Anticancer agents and use
View Patent ↗Provided herein are compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as desmethyl, desamino-pateamine A. Suitable analogs provide anticancer and antiproliferative effects in vivo and in vitro by a novel drug mechanism of action described herein for pateamine A, including inhibition of eIF4A-dependent translation initiation. As with pateamine A, as described herein, suitable analogs cause cell cycle arrest or induce apoptosis in transformed cells. However, toxicity of such compounds to slow growing normal cells is low. In addition, such analogs, like pateamine A, target translation initiation factors and are useful as anticancer and antiproliferative agents in subjects in need thereof. Moreover, the analogs, like pateamine A, are valuable molecular probes for evaluation of eukaryotic translation initiation and as lead compounds for development of improved anticancer agents.
1. A method of synthesizing a compound of formula (A):
wherein R is Br and R′ is —SO 2 C 6 H 4 CH 2 (CH 2 ) n C≡CSi(CH 3 ) 3 wherein n=1-5, comprising reacting a compound of formula (B):
in the presence of NH 2 NHSO 2 C 6 H 4 CH 2 (CH 2 ) n C≡CSi(CH 3 ) 3 , wherein n=1-5, and catalytic Al 2 O 3 .
2. A pharmaceutical composition comprising a pateamine A analog of formula (I):
and its pharmaceutically acceptable salts, wherein:
A-B is ethane, (F) and (Z)-ethene, (F) and (Z)-substituted ethene, or ethyne;
K 1 , K 2 and K 3 are hydrogen or alkyl (C=1-3) ;
Q is NH or O;
X is hydrogen;
Y is S, NH, or O;
Z is hydrogen;
R 1 is hydrogen or alkyl (C=1-3) ; and
R is selected from the following:
(a) an alkene of the formula:
wherein R 2 is selected from the group consisting of alkyl, alkylhydroxy, alkylalkoxy, alkylamino, alkylaminoalkyl and alkylaminodialkyl;
(b) an alkenylaryl of the formula:
wherein R 3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, trifluoromethane and fluoro;
(c) methyldienylpentyl of the formula:
wherein R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino, alkylamino and dialkylamino; and
(d) methylalkenylpentyl of the formula:
wherein R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino, alkylamino and dialkylamino,
and a pharmaceutically acceptable carrier.
3. The pharmaceutical composition of claim 2 , wherein the pateamine A analog of formula (I) is further defined as a compound of formula (II), or its pharmaceutically acceptable salts:
4. The method of claim 1 , further comprising reacting the compound of formula (A) with Bu 3 SnCH═CHC(CH 3 )═CHCH 2 N(CH 3 ) 2 , Pd 2 dba 3 and AsPh 3 to form a compound of formula (C):
wherein R is —SO 2 C 6 H 4 CH 2 (CH 2 ) n C≡CSi(CH 3 ) 3 and n=1-5.
5. The method of claim 4 , further comprising reacting the compound of formula (C) with a biotinylated azide of formula (B), 5 mol % of CuI, and N,N-diisopropylethylamine to form the compound of formula (D):
wherein n=1-5.
6. The pharmaceutical composition of claim 2 , wherein A-B is ethane.
7. The pharmaceutical composition of claim 2 , wherein A-B is (E) and (Z)-ethene.
8. The pharmaceutical composition of claim 2 , wherein A-B is (E) and (Z)-substituted ethene.
9. The pharmaceutical composition of claim 2 , wherein A-B is ethyne.
10. The pharmaceutical composition of claim 2 , wherein K 1 , K 2 and K 3 are hydrogen.
11. The pharmaceutical composition of claim 2 , wherein K 1 , K 2 and K 3 are alkyl (C=1-3) .
12. The pharmaceutical composition of claim 2 , wherein Q is NH.
13. The pharmaceutical composition of claim 2 , wherein Q is O.
14. The pharmaceutical composition of claim 2 , wherein R 1 is hydrogen.
15. The pharmaceutical composition of claim 2 , wherein R 1 is alkyl (C=1-3) .
16. The pharmaceutical composition of claim 2 , wherein R is alkyl, alkylhydroxy or alkylalkoxy.
17. The pharmaceutical composition of claim 2 , wherein R is alkylamino, alkylaminoalkyl or alkylaminodialkyl.
18. The pharmaceutical composition of claim 2 , wherein R 3 is alkyl, alkenyl or alkynyl.
19. The pharmaceutical composition of claim 2 , wherein R 3 is hydroxy or alkoxy.
20. The pharmaceutical composition of claim 2 , wherein R 3 is amino, alkylamino or dialkylamino.
21. The pharmaceutical composition of claim 2 , wherein R 3 is trifluoromethane or fluoro.
22. The pharmaceutical composition of claim 2 , wherein R is a methyldienylpentyl of the formula:
wherein R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl.
23. The pharmaceutical composition of claim 2 , wherein R is a methyldienylpentyl of the formula:
wherein R 4 is from the group consisting of hydroxy, alkoxy, amino, alkylamino and dialkylamino.
24. The pharmaceutical composition of claim 2 , wherein R is a methylalkenylpentyl of the formula:
wherein R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, amino, alkylamino and dialkylamino.
25. The pharmaceutical composition of claim 2 , wherein R is a methylalkenylpentyl of the formula:
wherein R 4 is selected from the group consisting of hydroxy and alkoxy.
26. The pharmaceutical composition of claim 2 , wherein R is a methylalkenylpentyl of the formula:
wherein R 4 is selected from the group consisting of amino, alkylamino and dialkylamino.
27. A method of treating leukemia in a subject in need of treatment, comprising administering to the subject a compound having the formula: